History

Vernalis as it is now came into being back in 2003, with the merger of British Biotech plc, Ribo Targets Holdings plc and Vernalis Group plc. The company currently has three sites:

  • Granta Park in Cambridge, UK - the base for our Research team
  • Winnersh, Berkshire, UK - where our Corporate Head Office is located and
  • Berwyn, USA - where our Commercial Operations are located.

With a team experienced in structure-based drug discovery since 1997, Vernalis Research has been committed to growing its external research collaborations. External endorsement of its discovery capabilities comes from major pharma companies around the world and which include: Novartis, Servier, GSK, Lundbeck, Genentech, Asahi Kasei Pharma and Taisho.

With six development candidates generated in the past seven years and cell active lead compounds against 15 targets the team has worked towards repeating the recent success for internally initiated programmes such as V158866 against FAAH, for the management of neuropathic pain and V158411 against Chk1, for cancer.

Below is a summary of the evolution and successes of Vernalis Research at Granta Park:

  • 1997 – structure-based drug discovery against RNA targets; established macromolecular NMR and fragment based drug discovery
  • 2000 – structure-based discovery of inhibitors of the 30S subunit of the ribosome; established crystallography
  • 2001 – research changed focus to oncology protein targets; development of the SeeDs fragment based discovery platform
  • 2003-4 – series of mergers brought CNS targets (gpcr pharmacology at Winnersh site), DMPK capability, clinical pipeline and a marketed product, frovatriptan
  • 2004 – HSP90 pre-clinical candidate partnered with Novartis
  • 2006 – research concentrated on Granta Park site with in-house projects on oncology targets
  • 2007 - first research collaboration with Servier; growing expertise in biophysical methods such as ITC and SPR
  • 2008 – the present – series of collaborations established with GSK, Genentech, Lundbeck, Servier, Asahi Kasei Pharma and Taisho on oncology, anti-inflammatory and CNS targets; in-house projects in oncology and anti-infectives

 

 

Latest News

Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations

Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...

 

NCE Pipeline

NCE-thumbnailExplore the pipeline ...

 

Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1